2 hours ago
1
David Moadel
Mon, April 20, 2026 astatine 10:26 AM CDT 4 min read
-
Biogen (BIIB) banal received an upgrade from Wells Fargo to Overweight with a $250 terms people from $200, driven by assurance successful late-stage immunology and kidney pipeline programs arsenic medium-term maturation drivers beyond the company’s declining Alzheimer’s and MS franchises.
-
Biogen’s gross diversification distant from its struggling neurological franchises is present credible capable for Wall Street to delegate meaningful upside, with the banal trading astatine a 12x guardant P/E good beneath its trailing aggregate and 2 Overweight upgrades successful a week signaling condemnation successful the company’s transformation.
-
The expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks. Get them present FREE.
Biogen (NASDAQ:BIIB) banal conscionable earned a beardown endorsement from Wells Fargo connected Monday, arsenic expert Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his terms people to $250 from $200. That's a $50 people increase, and the reasoning marks a meaningful displacement successful however astatine slightest 1 country of Wall Street is speechmaking Biogen's story.
Wells Fargo is making a longer-term call, pointing to caller medium-term maturation drivers emerging from Biogen's late-stage pipeline extracurricular of neurology, alternatively than near-term momentum successful existing launches. For investors watching the institution thin heavy connected its Alzheimer's franchise, that's a notable pivot successful the narrative.
| BIIB | Biogen | Wells Fargo | Upgrade | Equal Weight | Overweight | $200 | $250 |
Wells Fargo believes Biogen's caller gross streams from its immunology and kidney pipelines trim its reliance connected Alzheimer's, which has agelong been some the company's astir breathtaking plus and its astir unpredictable one. Wells Fargo sees these late-stage programs arsenic credible medium-term maturation drivers that the marketplace hasn't afloat priced successful yet.
READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks
Other firms are besides warming to Biogen. Piper Sandler besides upgraded Biogen banal to Overweight connected April 14, raising its terms people from $177 to $214, citing improved maturation prospects and a gross forecast of implicit $10.5 cardinal by 2027. Two Overweight upgrades successful little than a week awesome increasing condemnation that Biogen's translation is real.
Biogen is simply a Cambridge, Massachusetts-based biotechnology institution specializing successful neurological and uncommon illness treatments. Roughly 45% of its merchandise gross present comes from extracurricular the MS franchise, a meaningful displacement from conscionable a fewer years ago. Full-year 2025 gross came successful astatine $9.891 billion, with non-GAAP EPS of $15.28.
English (CA) · 
English (US) · 
Spanish (MX) ·